ClinicalTrials.gg

TargetBeta

RET

ret proto-oncogene · also PTC, CDHF12, RET51, CDHR16 · Cadherin related

7 programs in company-led studies act on RET, from 7 companies: 1 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
selpercatinibruleEli Lillyphase 4197 runningCCDC6, KIF5BNCIt
regorafenibruleBayerphase 4404 runningABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, TEKChEMBL
pralsetinibruleHoffmann-La Rochephase 473 runningCCDC6, KIF5BNCIt
quizartinibruleDaiichi Sankyophase 3225 runningCSF1R, FLT3, KIT, PDGFRA, PDGFRBChEMBL
RET Inhibitor HS-10365Hansoh Pharmaceutical Groupphase 233 running–the company's pipeline
TRK/RET Inhibitor ND-003ruleShenzhen NewDEL Biotechphase 233 running–NCIt
RET Inhibitor FHND5071Sino Biopharmaceuticalphase 110 running–the company's pipeline

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.